Search Results

ProMIS Neurosciences Inc. announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.

ProMIS Neurosciences, Inc. announced that the European Patent Office, Japanese Patent Office and IP Australia, the Australian patent office, have recently allowed composition of matter and method of use patent applications related to ProMIS Neurosciences’ lead product candidate, PMN310, for the treatment of Alzheimer’s disease .

ProMIS Neurosciences Inc., a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, announced that company management will participate in three upcoming investor conferences.

ProMIS Neurosciences Inc. today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.

ProMIS Neurosciences Inc., a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced a strategic leadership change.

ProMIS Neurosciences Inc. announced the publication of a paper titled, “Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies,” in the online journal, bioRxiv.

ProMIS Neurosciences Inc. today announced the publication of supportive preclinical data in the Journal of Biological Chemistry in an article titled, “Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1.”

ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update.